Definitive Contract 75N93018C00052

This is a cost-plus-fixed-fee definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to Meabco Inc. for the "ERMES EVALUATION OF RADIOMITIGATIVE EFFICACY AND SAFETY OF BP-C2" project. The contract has a ceiling value of $6,434,348.32 and a period of performance ending on April 30, 2025. The contract stems from a Broad Agency Announcement (BAA) seeking proposals to develop safe and effective medical countermeasures to...

The National Institute of Allergy and Infectious Diseases (NIAID) of the Department of Health and Human Services awarded a $6,620,728 cost-plus-fixed-fee contract to Xequel Bio, Inc. (doing business as FSR) to develop a topical therapeutic called GRANEXIN to mitigate cutaneous radiation injury. This contract was awarded under a prior NIAID Broad Agency Announcement that sought proposals for advanced development of medical countermeasures, including those targeting radiation exposure. The...

<p>This is a firm fixed-price purchase order contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, to RX Biosciences, LLC, a small disadvantaged business. The contract, valued at $4,130.00, is for the construction of a DNA library. The contract has a total small business set-aside designation and was awarded on August 13, 2013, with a completion date of September 12, 2013.</p>

<p>This is a $11,360.00 firm fixed price purchase order awarded by the National Institute of Allergy and Infectious Diseases (NIAID) to RX Biosciences, LLC for the construction of a phage display library. The award was made on October 27, 2015 with a completion date of February 24, 2016. RX Biosciences, LLC is a minority-owned, self-certified small disadvantaged business. The contract has no set-aside designation.</p>

This is a cost-plus-fixed-fee delivery order contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services (HHS), to SRI International, a non-profit research and development institute. The contract, valued at $715,633.86, is for radiation/nuclear medical countermeasure (MCM) product development support services, specifically the formulation of 3,4,3-Li(1,2-HOPO). This contract is not a set-aside and is part of a...

The U.S. National Institute of Allergy and Infectious Diseases (NIAID) awarded a $6,728,096.00 cost-plus-fixed-fee definitive contract to Myelo Therapeutics GmbH, a for-profit limited liability company, for the development of MYELO001 as an orally applied medical countermeasure to treat hematopoietic acute radiation syndrome. This contract, which has a completion date of January 16, 2025, stems from a Broad Agency Announcement seeking proposals to develop safe and effective medical...

This federal contract award to Innovation Pathways, LLC, a for-profit limited liability company, is for the pharmacological development of IPW-5371 fumarate as a radiation medical countermeasure for the treatment of delayed radiation lung injury under the FDA Animal Rule. The $3,499,688.00 cost-plus-fixed-fee contract was awarded by the National Institute of Allergy and Infectious Diseases, a civilian agency, and has no set-aside designation. The contract work supports research and development...

This is a prime contract award to Resilience Government Services, Inc. (doing business as Nanotherapeutics Inc.) by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the Department of Health and Human Services. The $14,898,362.53 cost-plus-fixed-fee contract is for biomedical research and development. It has a period of performance through December 31, 2011 and does not have a set-aside designation. Resilience Government Services is a technology-focused...

This is a $100,361,311 cost-plus-fixed-fee contract awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR) to the non-profit research organization MRIGlobal, also known as Midwest Research Institute, for the development of &quot;Biodosimetry High-Throughput Diagnostic Tests.&quot; The contract supports the creation of diagnostic tests to evaluate radiation exposure, which is a critical capability for public health emergency preparedness. As a prime contractor,...

This is a $1,633,610.00 time and materials purchase order contract awarded by the National Heart, Lung and Blood Institute (NHLBI), a component of the National Institutes of Health (NIH), to Biocomx, a minority-owned nonprofit organization. The contract is part of the NIH's National Institute of Biomedical Imaging and Bioengineering (NIBIB) COVID-19 RADx initiative, which aims to accelerate the development and implementation of rapid innovative diagnostics for COVID-19. Under this contract,...